The Food and Drug Administration approved the dual immunotherapy of Opdivo and Yervoy for the treatment of patients with advanced hepatocellular carcinoma. Heres what you need to know. This is the only dual immunotherapy approved by the FDA in this setting of patients with HCC and was based on the results of the phase 1/2 CheckMate-040 trial
Recent Comments